Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling

被引:113
作者
Quade, BJ
Wang, TY
Sornberger, K
Dal Cin, P
Mutter, GL
Morton, CC
机构
[1] Brigham & Womens Hosp, Div Womens & Perinatal Pathol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Mackay Mem Hosp, Dept Pathol, Taipei, Taiwan
关键词
D O I
10.1002/gcc.20018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Uterine smooth muscle tumors range from the very common benign leiomyoma to the uncommon, but frequently lethal, leiomyosarcoma. Morphological and clinical differences between these tumors are presumed to result from differences in gene expression. To test this hypothesis, RNAs from four normal uterine myometria, seven uterine leiomyomas, and nine uterine leiomyosarcomas were profiled using microarrays of oligonuclecitides representing about 7,000 unique probe sets. RNAs whose levels distinguished any of the three sample types were selected by analysis of variance (ANOVA). The 153 (2.2% of the total) probe sets representing 146 unique genes with the highest test statistic selected for further analysis met minimum ratio and range thresholds between groups. Cluster analysis distinguished benign and malignant samples at the first node, and myometrium and leiomyoma were resolved in a secondary node. Downregulation of specific genes in uterine leiomyosarcoma was the most common pattern of differential gene expression selected by the three-way ANOVA Four extrauterine leiomyosarcomas had profiles most similar to that of the uterine leiomyosarcomas. Functional analysis of the 146 genes did not reveal any strong biological theme. These genes were distributed throughout. the genome, but there was slight overrepresentation of genes on 1p and 2q. These genes define a tumor signature for uterine smooth muscle neoplasia, and they suggest that the molecular pathways in leiomyoma and leiomyosarcoma are distinct. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:97 / 108
页数:12
相关论文
共 27 条
[1]   THE FREQUENCY OF UTERINE LEIOMYOMAS [J].
CRAMER, SF ;
PATEL, A .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1990, 94 (04) :435-438
[2]   T(10-17) AS THE SOLE CHROMOSOME CHANGE IN A UTERINE LEIOMYOSARCOMA [J].
DALCIN, P ;
BOGHOSIAN, L ;
CRICKARD, K ;
SANDBERG, AA .
CANCER GENETICS AND CYTOGENETICS, 1988, 32 (02) :263-266
[3]  
FLETCHER JA, 1990, CANCER RES, V50, P4092
[4]  
Gattas GJF, 1999, GENE CHROMOSOME CANC, V25, P316, DOI 10.1002/(SICI)1098-2264(199908)25:4<316::AID-GCC2>3.3.CO
[5]  
2-S
[6]  
HOSACK DA, 2003, GENOME BIOL, V4, pP4, DOI DOI 10.1186/GB-2003-4-6-P4
[7]   Genomic alterations in uterine leiomyosarcomas: Potential markers for clinical diagnosis and prognosis [J].
Hu, J ;
Khanna, V ;
Jones, M ;
Surti, U .
GENES CHROMOSOMES & CANCER, 2001, 31 (02) :117-124
[8]  
Kiuru M, 2002, CANCER RES, V62, P4554
[9]   Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-β3 (TGFβ3) and altered responses to the antiproliferative effects of TGFβ [J].
Lee, BS ;
Nowak, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) :913-920
[10]   PCOLCE deletion and expression analyses in uterine leiomyomata [J].
Ligon, AH ;
Scott, IC ;
Takahara, K ;
Greenspan, DS ;
Morton, CC .
CANCER GENETICS AND CYTOGENETICS, 2002, 137 (02) :133-137